Comment from Society of Quality Assurance

Summary: The Society of Quality Assurance (SQA) provides specific technical feedback and proposed wording revisions to the FDA's draft guidance on AI in drug and biological product regulation. They advocate for clearer definitions, more explicit requirements for monitoring bias and data drift, and the inclusion of risk-based categories aligned with international standards.